Yahoo · Oct 8, 2026
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast Cancer
Pfizer's Tukysa combo regimen wins FDA approval for frontline maintenance breast cancer treatment, extending its use beyond the second-line setting.
IN
NASDAQ · INO
Inovio Pharmaceuticals, Inc.
Healthcare · Biotechnology
$1.01
Up+$0.01 (+1.00%)
Updated Oct 21, 2026, 2:57 AM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 114.68M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.56 – $2.72
- Volume
- 10.81M
- Avg. volume
- 1.16M
Price performance · INO
INO price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 20, 2026
INO closed at $1.01 after 21 trading sessions, down 21.71% for the selected period.
- Last close
- $1.01
- Period change
- -21.71%
- Period low
- $0.99
- Period high
- $1.29
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | $1.01 | $1.06 | $0.99 | $1.01 | 10.81M |
| Oct 19, 2026 | $1.01 | $1.02 | $0.98 | $1.00 | 2.12M |
| Oct 16, 2026 | $1.06 | $1.06 | $0.9864 | $0.9901 | 2.06M |
| Oct 15, 2026 | $0.9606 | $1.06 | $0.9606 | $1.04 | 1.76M |
| Oct 14, 2026 | $1.00 | $1.02 | $0.9583 | $0.986 | 3M |
| Oct 13, 2026 | $1.11 | $1.11 | $0.95 | $0.9982 | 8.56M |
| Oct 12, 2026 | $1.16 | $1.18 | $1.09 | $1.105 | 2.33M |
| Oct 9, 2026 | $1.10 | $1.15 | $1.07 | $1.15 | 2.89M |
| Oct 8, 2026 | $1.17 | $1.175 | $1.08 | $1.09 | 3.21M |
| Oct 7, 2026 | $1.12 | $1.19 | $1.11 | $1.155 | 2.8M |
| Oct 6, 2026 | $1.15 | $1.17 | $1.12 | $1.13 | 2.01M |
| Oct 5, 2026 | $1.20 | $1.21 | $1.11 | $1.15 | 2.96M |
| Oct 2, 2026 | $1.22 | $1.23 | $1.16 | $1.16 | 2.92M |
| Oct 1, 2026 | $1.24 | $1.26 | $1.20 | $1.21 | 1.94M |
| Sep 30, 2026 | $1.14 | $1.235 | $1.13 | $1.22 | 2.69M |
| Sep 29, 2026 | $1.18 | $1.18 | $1.10 | $1.11 | 3.06M |
| Sep 28, 2026 | $1.18 | $1.21 | $1.14 | $1.17 | 1.9M |
| Sep 25, 2026 | $1.22 | $1.23 | $1.17 | $1.18 | 2.25M |
| Sep 24, 2026 | $1.26 | $1.26 | $1.18 | $1.21 | 2.85M |
| Sep 23, 2026 | $1.30 | $1.3076 | $1.24 | $1.25 | 3.03M |
| Sep 22, 2026 | $1.25 | $1.335 | $1.25 | $1.29 | 2.93M |
Latest INO news
The latest Smart Investors Daily articles mentioning INO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
INO research
Overview
Company profile and research snapshot.
Company profile
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $6.00
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Jefferies | Buy | — |
| Aug 3, 2026 | Piper Sandler | Overweight | — |
| Jun 1, 2026 | HC Wainwright & Co. | Neutral | — |
| Nov 14, 2025 | Piper Sandler | Overweight | — |
| Aug 14, 2025 | HC Wainwright & Co. | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 5, 2026
PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know
Precigen is building momentum with Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline.
Yahoo · Sep 24, 2026
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Precigen's Papzimeos is gaining commercial momentum, while its pipeline potential through the AdenoVerse platform could create new growth opportunities.
Yahoo · Sep 14, 2026
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock?
PGEN's Papzimeos is driving strong early sales, while European expansion and pipeline progress could shape the stock's growth outlook.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
